Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rifaximin - Alfasigma

Next Previous
Drug Profile

Rifaximin - Alfasigma

Alternative Names: Dermodis; EIR formulation of rifaximin - Salix Pharmaceuticals; Flonorm; L-105; Lumenax; Normix; RedActive®; Rifacol; Rifaxidin®; Rifaximin soluble solid dispersion tablet; Rifaximin SSD; Rifaximin-a 550mg; rifaximin-alpha; Rifxima; SLX-G1043; SLX-G1063; SLX-L1042; SLX-L1044; Spiraxin; Targaxan 550; Tixtar; Xifaxan; Xifaxan 550mg; XIFAXAN550; Xifaxanta; Zaxine

Latest Information Update: 25 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; Alfasigma; ASKA Pharmaceutical; Bausch Health Companies; Lupin; Norgine; Salix Pharmaceuticals; University of Washington; Yokohama City University
  • Class Anti-infectives; Anti-inflammatories; Antianaemics; Antibacterials; Antidiarrhoeals; Hepatoprotectants; Irritable bowel syndrome therapies; Rifamycins; Skin disorder therapies; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Hepatic encephalopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diverticulitis; Hepatic encephalopathy; Hyperammonaemia; Intestinal infections; Irritable bowel syndrome; Skin and soft tissue infections; Traveller's diarrhoea
  • Phase III Crohn's disease; Liver disorders
  • Phase II Intestinal obstruction; Rosacea; Sickle cell anaemia
  • Phase Unknown COVID 2019 infections
  • No development reported Unspecified
  • Discontinued Bacterial vaginosis; Clostridium difficile infections; Pouchitis; Shigella infections

Most Recent Events

  • 25 Apr 2024 Bausch Health Companies plans to submit NDA for Liver disorders (prevention of complications of decompensated cirrhosis) in 2026
  • 05 Apr 2024 United States District Court for the District of New Jersey dismisses lawsuit filed by Bausch Health Companies and Salix Pharmaceuticals against Amneal Pharmaceuticals for alleged patent infringement over generic XIFAXAN® (rifaximin) 550 mg tablets
  • 21 Mar 2024 Bausch Health Americas completes enrollment in phase III trial in Hepatic encephalopathy (Prevention) in Puerto Rico, Canada, Australia, USA (PO) (NCT05071716)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top